[1]
Siniscalchi A, De Sarro G, Pacifici R, Pisani E, Sanguigni S, Gallelli L. Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice. Psychopharmacol Bull 2019; 49(1): 70-9.
[PMID: 30858640]
[PMID: 30858640]
[2]
Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011; 123(7): 750-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.974675] [PMID: 21311083]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.974675] [PMID: 21311083]
[3]
Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019; 394: 139-47.
[http://dx.doi.org/10.1016/S0140-6736(19)31053-0] [PMID: 31128925]
[http://dx.doi.org/10.1016/S0140-6736(19)31053-0] [PMID: 31128925]
[4]
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28(11): 2109-18.
[http://dx.doi.org/10.1161/01.STR.28.11.2109] [PMID: 9368550]
[http://dx.doi.org/10.1161/01.STR.28.11.2109] [PMID: 9368550]
[5]
Siniscalchi A, Gallelli L, Malferrari G, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol 2014; 25(2): 131-7.
[http://dx.doi.org/10.1515/jbcpp-2013-0121] [PMID: 24515999]
[http://dx.doi.org/10.1515/jbcpp-2013-0121] [PMID: 24515999]
[6]
Yang C, Hawkins KE, Doré S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol 2019; 316(2): C135-53.
[http://dx.doi.org/10.1152/ajpcell.00136.2018] [PMID: 30379577]
[http://dx.doi.org/10.1152/ajpcell.00136.2018] [PMID: 30379577]
[7]
Tanaka T, Ihara M. Post-stroke epilepsy. Neurochem Int 2017; 107: 219-28.
[http://dx.doi.org/10.1016/j.neuint.2017.02.002] [PMID: 28202284]
[http://dx.doi.org/10.1016/j.neuint.2017.02.002] [PMID: 28202284]
[8]
Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol 2015; 7(1)a020412
[http://dx.doi.org/10.1101/cshperspect.a020412] [PMID: 25561720]
[http://dx.doi.org/10.1101/cshperspect.a020412] [PMID: 25561720]
[9]
Sharma HS, Sjöquist P-O, Ali SF. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 2007; 13(18): 1903-23.
[http://dx.doi.org/10.2174/138161207780858375] [PMID: 17584116]
[http://dx.doi.org/10.2174/138161207780858375] [PMID: 17584116]
[10]
Siniscalchi A, Sztajzel R, Bonci A, Malferrari G, De Sarro G, Gallelli L. Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis? Curr Vasc Pharmacol 2016; 14(3): 304-6.
[http://dx.doi.org/10.2174/1570161114999160204151620] [PMID: 26845684]
[http://dx.doi.org/10.2174/1570161114999160204151620] [PMID: 26845684]
[11]
Parrado-Fernández C, Blennow K, Hansson M, Leoni V, Cedazo-Minguez A, Björkhem I. Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers. J Cell Mol Med 2018; 22(10): 5151-4.
[http://dx.doi.org/10.1111/jcmm.13767] [PMID: 30054982]
[http://dx.doi.org/10.1111/jcmm.13767] [PMID: 30054982]
[12]
Leigh R, Jen SS, Hillis AE, Krakauer JW, Barker PB. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke 2014; 45(7): 2030-5.
[http://dx.doi.org/10.1161/STROKEAHA.114.005249] [PMID: 24876245]
[http://dx.doi.org/10.1161/STROKEAHA.114.005249] [PMID: 24876245]
[13]
Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004; 24(9): 945-63.
[http://dx.doi.org/10.1097/01.WCB.0000137868.50767.E8] [PMID: 15356416]
[http://dx.doi.org/10.1097/01.WCB.0000137868.50767.E8] [PMID: 15356416]
[14]
Li Y, Zhong W, Jiang Z, Tang X. New progress in the approaches for blood-brain barrier protection in acute ischemic stroke. Brain Res Bull 2019; 144: 46-57.
[http://dx.doi.org/10.1016/j.brainresbull.2018.11.006] [PMID: 30448453]
[http://dx.doi.org/10.1016/j.brainresbull.2018.11.006] [PMID: 30448453]
[15]
Bektas H, Wu TC, Kasam M, et al. Increased blood-brain barrier permeability on perfusion CT might predict malignant middle cerebral artery infarction. Stroke 2010; 41(11): 2539-44.
[http://dx.doi.org/10.1161/STROKEAHA.110.591362] [PMID: 20847316]
[http://dx.doi.org/10.1161/STROKEAHA.110.591362] [PMID: 20847316]
Article Metrics
![Wayfinder Image](/images/wayfinder.jpg)